Lixenatide (GLP-1 RA) was noninferior to placebo in reduction of primary composite endpoint (CV death, nonfatal MI, nonfatal stroke, or hospitalization for UA; HR = 1.02), individual components of primary composite endpoint, and overall mortality (HR = 1.13). The glycated hemoglobin was significantly reduced. This evidence concerns the gene GLP1R and stroke disorder.